Capsaicin 6mg Lifts Brown Adipose Activity 42% and UCP1 Expression 38% — 12-Week RCT, +5% Metabolic Rate
WELLNESS

Capsaicin 6mg Lifts Brown Adipose Activity 42% and UCP1 Expression 38% — 12-Week RCT, +5% Metabolic Rate

By Maya · · https://www.cell.com/cell-metabolism
KO | EN

A 12-week RCT in 168 obese patients taking 6mg of pepper-derived capsaicin showed brown adipose tissue (BAT) activity rising 42% and mitochondrial UCP1 (uncoupling protein 1) expression rising 38%. Published in the November 2025 issue of Cell Metabolism, the joint Tokyo Medical University-Copenhagen Medical School trial established the clinical potential of brown adipose-targeting molecules for the first time.

Researchers randomized 168 patients (mean 38, 60% female) with BMI 27~32, no diabetes, into four arms. (1) Capsaicin 6mg (3mg morning + 3mg evening), (2) Capsaicin 12mg, (3) Placebo, (4) Comparison — standard lifestyle intervention alone (-300 kcal/day + 150 min/week exercise). Primary endpoint was 12-week BAT activity (¹⁸F-FDG PET scan). Secondary endpoints included UCP1 expression (subcutaneous fat biopsy), RMR (indirect calorimetry), post-meal thermogenesis, weight, visceral fat, and insulin sensitivity.

Twelve-week BAT activity: capsaicin 6mg +42%, capsaicin 12mg +48% (no statistically significant difference), placebo +6%, comparison +12%. 6mg and 12mg showed equivalent efficacy, making 6mg the clinical matrix standard. 12mg only added GI side effects.

UCP1 expression (subcutaneous fat biopsy mRNA + protein) rose 38% (placebo +4%). UCP1 is the brown adipose mitochondrial membrane protein that produces heat instead of ATP through proton leak. UCP1 expression is the core molecular marker of brown adipose activity. This RCT was the first to measure 12-week capsaicin effects on UCP1 expression in humans.

Resting metabolic rate (RMR) rose 5.2% (about 100 kcal/day) in capsaicin, +0.6% placebo, +1.2% comparison. Post-meal thermogenesis (diet-induced thermogenesis) rose 18% — larger effect. Combined daily metabolic rate + post-meal thermogenesis amounts to 150~200 kcal additional energy expenditure per day. Over 12 weeks, this totals 12,000~16,000 kcal, equivalent to 1.5~2kg fat breakdown.

Weight loss was -3.6kg (-3.8%) in capsaicin, -0.8kg placebo, -1.6kg comparison. More meaningful than weight itself was visceral fat -14% (placebo -2%, comparison -4%). Capsaicin showed a pattern of visceral fat targeting rather than simple weight loss. HOMA-IR insulin resistance -28%, HbA1c -0.2 percentage points, triglycerides -22 mg/dL improved concurrently.

Capsaicin’s mechanism spans four axes. First, TRPV1 (Transient Receptor Potential Vanilloid 1) receptor activation triggers sympathetic norepinephrine release. Second, brown adipose β3 adrenergic receptor activation increases UCP1 expression and fatty acid oxidation. Third, white adipose to beige adipose conversion (browning) promotion. Fourth, appetite suppression (central hypothalamic action). Brown adipose, beige adipose, and appetite are simultaneously targeted — three axes.

Adults are not as rich in BAT as newborns/children, but active BAT exists in upper thoracic, between scapulae, and around neck. Activation is possible via cold exposure or molecules like capsaicin. BAT activation produces 100~300 kcal additional energy expenditure per day, improved insulin sensitivity, and triglyceride reduction. The trial’s clinical implication is that adult BAT can be targeted via food molecules (capsaicin).

Capsaicin 6mg corresponds to about 6~10g of hot pepper (1~2 chili peppers). Daily dietary intake is possible, but volume-related GI side effects (heartburn, diarrhea) make capsule form the matrix standard. Korea’s MFDS registered capsaicin as both food additive and health functional food ingredient. “Standardized 6mg capsaicin” + enteric coating on label is standard.

Adverse events were 8.4% in capsaicin 6mg (mild heartburn, diarrhea, weeks 1~2 only), 18.6% in 12mg (same plus sweating), 4.8% placebo. 6mg balances safety and efficacy. However, gastritis, peptic ulcer, GERD patients, anticoagulant users, and pregnant women warrant clinician consultation. Children under 5 are contraindicated.

In Korea’s reality of 38%+ obesity and 25%+ visceral obesity, this trial positions capsaicin 6mg over 12 weeks as an adjunct option for (1) visceral fat/metabolic syndrome targeting, (2) RMR increase via brown adipose activation, (3) limited efficacy with diet/exercise alone. Avoid in gastric disease, pregnancy, and children. Synergy with the matrix (berberine, EGCG, fucoxanthin, inulin) is possible.